In this report, we present in more detail the case of a patient with a triple wild-type, class-2 MAP2K1-mutant AJCC stage IV-M1d melanoma, treated in the TraMel-WT trial, who had a deep and durable response to MEK-inhibitor treatment with excellent treatment tolerance (12). Here, MAP2K1 is linked to melanoma.